You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer

  • Technology appraisal guidance
  • Reference number: TA1150
  • Published:  06 May 2026
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Final draft guidance
  2. Declaration of interests
  3. Draft guidance: 1
  4. Invitation to participate
  5. Notes

History

Documents created during the development process.

Final draft guidance

  • Final draft guidance

  • Final draft guidance (PDF 296 KB)

    Published:
    21 April 2026
  • Committee papers (PDF 2.35 MB)

    Published:
    21 April 2026
  • Public committee slides (PDF 974 KB)

    Published:
    21 April 2026
  • Equality impact assessment (downloadable version) (PDF 136 KB)

    Published:
    21 April 2026

Declaration of interests

  • Register of interests (PDF 161 KB)

    Published:
    17 October 2025

Draft guidance: 1

  • Draft guidance: 1

  • Draft guidance (downloadable version) (PDF 242 KB)

    Published:
    03 June 2025
  • Draft guidance (online commenting)

  • Committee papers (PDF 6.67 MB)

    Published:
    03 June 2025
  • Public committee slides (PDF 712 KB)

    Published:
    03 June 2025
  • Equality impact assessment (downloadable version) (PDF 121 KB)

    Published:
    03 June 2025

Invitation to participate

  • Final scope (PDF 182 KB)

    Published:
    01 October 2024
  • Final stakeholder list (PDF 184 KB)

    Published:
    01 October 2024
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 220 KB)

    Published:
    01 October 2024
  • Equality impact assessment (scoping) (PDF 125 KB)

    Published:
    01 October 2024

Notes

  • Note

  • Note

Back to top